Neon Therapeutics announced the completion of enrollment in NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with Keytruda and chemotherapy in patients with untreated advanced or metastatic non-small cell lung cancer, or NSCLC. NEO-PV-01 is a personal neoantigen vaccine custom-designed and manufactured based on the neoantigens identified by Neon’s proprietary bioinformatics engine, Recon, as being the most therapeutically relevant for an individual patient.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.